Hypercalcemia affects up to 30% of patients with cancer. 1 It has been seen in most cancers but is most common in patients with non-small cell lung cancer, breast cancer, multiple myeloma, head and ...

Hypercalcemia has been reported to occur in up to 30% of patients who have a malignancy. Hypercalcemia is most common in those who have later-stage malignancies and predicts a poor prognosis for those ...

Hypercalcemia of malignancy (HCM) is the most common metabolic complication seen in patients with cancer, and is associated with a high degree of morbidity and mortality. It affects an estimated 2%–30 ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

A real-world cohort study showed no difference in efficacy between denosumab and bisphosphonates in treating inpatients with hypercalcemia of malignancy. “Prospective randomized trials are warranted ...

Experts provide the first framework for treating a common and life-threatening metabolic complication of cancer known as hypercalcemia of malignancy in the Endocrine Society's new Clinical Practice ...

Early in the course of the development of these agents, haloperidol was found to cause not only hypokinetic and hyperkinetic motor disorders but also a potentially fatal syndrome of muscle rigidity ...